Abstract:CDK2, which interacts with cyclin A and cyclin E, is an important member of the CDK family. Having been proved to be associated with many diseases for its vital role in cell cycle, CDK2 is a promising target of anti-cancer drugs dealing with cell cycle disorders. In the present work, a total of 111 pyrazolo[1,5-a]pyrimidines (PHTPPs) as CDK2/cyclin A inhibitors were studied to conduct three-dimensional quantitative structure-activity (3D-QSAR) analyses. The optimal comparative molecular similarity indices analysis (CoMSIA) model shows that Q(2) = 0.516, R-ncv(2) = 0.912, R-pre(2) = 0.914, R-m(2) = 0.843, SEP = 0.812, SEE = 0.347 with 10 components using steric, hydrophobic and H-bond donor field descriptors, indicating its effective internal and external predictive capacity. The contour maps further indicate that (1) bulky substituents in R-1 are beneficial while H-bond donor groups at this position are detrimental; (2) hydrophobic contributions in the R-2 area are favorable; (3) large and hydrophilic groups are well tolerated at the R-3 position (a close H-bond donor moiety is favorable while a distal H-bond donor moiety in this area is disfavored); (4) bulky and hydrophobic features in the R-4 region are beneficial for the biological activities and (5) the 7-N-aryl substitution is crucial to boost the inhibitory activities of the PHTPP inhibitors. Finally, docking and MD simulations demostrate that PHTPP derivatives are stabilized in a 'flying bat' conformation mainly through the H-bond interactions and hydrophobic contacts. Comparative studies indicate that PHTPP derivatives fit well within the ATP binding cleft in CDK2, with the core heterocyclic ring overlapping significantly with the adenine group of ATP despite a small deflection. In comparison to numerous other inhibitors binding to the ATP pocket, PHTPP analogues follow the binding fashion of purine inhibitors of this kinase. It is anticipated that the binding mechanism and structural features of PHTPP inhibitors studied in the present work will benefit the discovery of more potent CDK2 inhibitors, and the valid pyrazolo[1,5-a]pyrimidine-7-N-yl inhibitors will soon emerge from the large number of screening programmes to enter in clinical studies.

Using 3D-QSAR and Molecular Docking Insight into Inhibitors Binding with Complex-Associated Kinases CDK8

3D-QSAR Study for Inhibitors of Cyclin-Dependent Kinase 4

Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.

Development of in Silico Models for Pyrazoles and Pyrimidine Derivatives As Cyclin-Dependent Kinase 2 Inhibitors

Molecular-docking-guided 3D-QSAR Studies of Substituted Isoquinoline-1,3-(2h,4h)-diones As Cyclin-Dependent Kinase 4 (CDK4) Inhibitors.

Molecular Docking, QSAR and Molecular Dynamics Simulation on Phosphorus Containing Pyrimidines As CDK9 Inhibitors

3D-QSAR and Molecular Docking Study on Selectivity of Indolocarbazole Series As Cyclin-Dependent Kinase Inhibitors

D-QSAR studies on pyrimidine analogues as cyclin-dependent kinase 1 inhibitors

3D-QSAR and Docking Studies on Pyrazolo[4,3-H]qinazoline-3-carboxamides As Cyclin-Dependent Kinase 2 (CDK2) Inhibitors.

Insight into the Interactions Between Novel Isoquinolin-1,3-dione Derivatives and Cyclin-Dependent Kinase 4 Combining QSAR and Molecular Docking.

3D-QSAR study of c-Src kinase inhibitors based on docking

3D-QSAR and Molecular Docking Approaches for the Identification of Novel Phyto-inhibitors of the Cyclin-dependent Kinase 4

An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.

Molecular Mechanism Concerning Conformational Changes of CDK2 Mediated by Binding of Inhibitors Using Molecular Dynamics Simulations and Principal Component Analysis

Effect of Substituents in Different Positions of Aminothiazole Hinge-Binding Scaffolds on Inhibitor–CDK2 Association Probed by Interaction Entropy Method

Molecular Docking and 3D-QSAR Studies on Checkpoint Kinase 1 Inhibitors

3D-QSAR Study of Chk1 Kinase Inhibitors Based on Docking

Discovery of 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine as Novel Cyclin-dependent Kinases 4 and 6 Dual Inhibitors via 3<i>D</i>-QSAR and Molecular Simulation

Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation

Computational Analysis for Residue-Specific CDK2-Inhibitor Bindings

3D-QSAR Studies on a Series of Inhibitors Docked into a New Homology Model of the DNA-PK Receptor.